Trial Profile
Efficacy and safety of retreatment regimen of sofosbuvir with ombitasvir/paritaprevir/ritonavir plus ribavirin in patients with HCV genotype 4 infection
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Mar 2018
Price :
$35
*
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 20 Mar 2018 New trial record
- 15 Mar 2018 Retreatment efficacy and safety results were published in the Digestive Diseases and Sciences